Trial Profile
NOPHO-DBH AML 2012 Protocol Research study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years NOPHO-DBH AML protocol. Research study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Daunorubicin (Primary) ; Fludarabine (Primary) ; Cytarabine; Etoposide; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms AML 2012; NOPHO-DBH AML 2012
- Sponsors Ixaka
- 28 Apr 2022 Planned number of patients changed from 325 to 850.
- 15 Apr 2013 New source identified and integrated: ClinicalTrials.gov record.
- 23 Feb 2013 Additional lead trial centres identified as reported by European Clinical Trials Database.